2024 RETpositive/LUNGevity Translational Research Award Program for RET-positive Cancer RFA

RETpositive is partnering with LUNGevity Foundation (“LUNGevity”) to issue an RFA specific to the study of RET-positive cancers. The research funded through this program is expected to have a direct impact on the outcomes of patients with advanced RET-positive cancer, but innovative proposals that address other unmet needs in the RET-positive cancer space are also invited for submission.